Despite decades of research into the pathology mechanisms of Parkinson's disease (PD),
disease-modifying therapy of PD is scarce. Thus, searching for new drugs or more effective …

Clinical studies to date have failed to establish therapeutic benefit of glial cell-derived
neurotrophic factor (GDNF) in Parkinson's disease (PD). In contrast to previous nonclinical …

Background: Levodopa remains the gold‐standard treatment for PD. However, it becomes
less effective as the disease progresses and produces debilitating side effects, such as …

Current research into Parkinson's disease (PD) is directed at developing novel agents and
strategies for improved symptomatic management. The aim of this research is to provide …

Current physiological studies emphasize the role of neuronal oscillations and
synchronization in the pathophysiology of Parkinson's disease; however, little is known …

Abstract Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the
role of this 5-HT injury—besides the dopaminergic one in the parkinsonian symptomatology …

Studies in MPTP‐lesioned nonhuman primates have demonstrated the potential of
nondopaminergic drugs in reducing the problems of levodopa‐induced dyskinesia (LID) …

The degeneration of nigral dopaminergic neurons in Parkinson's disease is believed to be
associated with a glial reaction and inflammatory changes. In turn, local factors may induce …

We investigated the safety and neuroregenerative potential of an adeno-associated virus
(AAV2) containing human glial cell line-derived neurotrophic factor (GDNF) in an MPTP …

The main medication for idiopathic Parkinson disease is l-Dopa. Drug efficacy declines
steadily in part because the converting enzyme, aromatic l-amino acid decarboxylase …